Organoidsciences Ltd. (KOSDAQ:476040)
30,450
+600 (2.01%)
At close: Aug 4, 2025, 3:30 PM KST
Chimerix Balance Sheet
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 |
---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Cash & Equivalents | 1,946 | 2,453 | 4,995 |
Short-Term Investments | 4,363 | 16,724 | 25,434 |
Trading Asset Securities | 9,891 | 3,121 | - |
Cash & Short-Term Investments | 16,199 | 22,298 | 30,429 |
Cash Growth | -27.35% | -26.72% | - |
Accounts Receivable | 230.51 | 442.77 | 49.27 |
Other Receivables | 53.39 | 218.35 | 298.55 |
Receivables | 283.9 | 661.12 | 347.82 |
Inventory | - | 26.23 | - |
Prepaid Expenses | 225.31 | 118.65 | 243.44 |
Other Current Assets | 189.27 | 269.46 | 115.87 |
Total Current Assets | 16,898 | 23,373 | 31,136 |
Property, Plant & Equipment | 7,212 | 7,874 | 7,381 |
Long-Term Investments | 3.3 | 0 | -0 |
Other Intangible Assets | 527.29 | 295.56 | 110.29 |
Long-Term Accounts Receivable | -0 | -0 | - |
Other Long-Term Assets | 1,252 | 1,213 | 1,132 |
Total Assets | 25,892 | 32,755 | 39,760 |
Accounts Payable | 17.03 | 14.88 | - |
Accrued Expenses | 297.57 | 332.45 | 158.58 |
Short-Term Debt | 3,000 | 300 | 300 |
Current Portion of Long-Term Debt | 167.18 | - | - |
Current Portion of Leases | 440.26 | 378.71 | 502.43 |
Current Income Taxes Payable | - | 0.74 | - |
Other Current Liabilities | 1,129 | 62,242 | 38,253 |
Total Current Liabilities | 5,051 | 63,269 | 39,214 |
Long-Term Debt | 2,533 | 2,000 | 2,000 |
Long-Term Leases | 1,952 | 2,207 | 1,523 |
Other Long-Term Liabilities | 192.63 | 313.58 | 260.6 |
Total Liabilities | 10,600 | 68,360 | 43,303 |
Common Stock | 2,635 | 1,433 | 1,433 |
Additional Paid-In Capital | 101,753 | 85.06 | 85.06 |
Retained Earnings | -91,664 | -80,409 | -41,740 |
Comprehensive Income & Other | 2,589 | 1,553 | 661.66 |
Total Common Equity | 15,313 | -77,338 | -39,560 |
Minority Interest | -19.92 | 69.14 | - |
Shareholders' Equity | 15,293 | -35,604 | -3,543 |
Total Liabilities & Equity | 25,892 | 32,755 | 39,760 |
Total Debt | 8,092 | 4,886 | 4,325 |
Net Cash (Debt) | 8,107 | 17,412 | 26,104 |
Net Cash Growth | -53.44% | -33.30% | - |
Net Cash Per Share | 1939.71 | 6075.69 | 9108.91 |
Filing Date Shares Outstanding | 5.27 | 2.87 | 2.87 |
Total Common Shares Outstanding | 5.27 | 2.87 | 2.87 |
Working Capital | 11,846 | -39,896 | -8,077 |
Book Value Per Share | 2905.63 | -26986.45 | -13804.25 |
Tangible Book Value | 14,785 | -77,633 | -39,671 |
Tangible Book Value Per Share | 2805.58 | -27089.59 | -13842.74 |
Land | 837.27 | 837.27 | 837.27 |
Buildings | 1,838 | 1,838 | 1,838 |
Machinery | 2,516 | 1,970 | 1,552 |
Construction In Progress | 25.1 | 202.09 | 268.2 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.